Intracellular Disposal of Incompletely Folded Human alpha 1-Antitrypsin Involves Release from Calnexin and Post-translational Trimming of Asparagine-linked Oligosaccharides*

(Received for publication, November 22, 1996, and in revised form, January 13, 1997)

Yan Liu , Priya Choudhury , Christopher M. Cabral and Richard N. Sifers §

From the  Department of Pathology, Section of Molecular Pathobiology and the § Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Protection of lung elastin fibers from proteolytic destruction is compromised by inefficient secretion of incompletely folded allelic variants of human alpha 1-antitrypsin from hepatocytes. Pulse-chase radiolabeling with [35S]methionine and sucrose gradient sedimentation and coimmunoprecipitation techniques were employed to investigate quality control of human alpha 1-antitrypsin secretion from stably transfected mouse hepatoma cells. The secretion-incompetent variant null(Hong Kong) (Sifers, R. N., Brashears-Macatee, S., Kidd, V. J., Muensch, H., and Woo, S. L. C. (1988) J. Biol. Chem. 263, 7330-7335) cannot fold into a functional conformation and was quantitatively associated with the molecular chaperone calnexin following biosynthesis. Assembly with calnexin required cotranslational trimming of glucose from asparagine-linked oligosaccharides. Intracellular disposal of pulse-radiolabeled molecules coincided with their release from calnexin. Released monomers and intracellular disposal were nonexistent in cells chased with cycloheximide, an inhibitor of protein synthesis. Post-translational trimming of asparagine-linked oligosaccharides and intracellular disposal were abrogated by 1-deoxymannojirimycin, an inhibitor of alpha -mannosidase activity, without affecting the monomer population. The data are consistent with a recently proposed quality control model (Hammond, C., Braakman, I., and Helenius, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 913-917) in which intracellular disposal requires dissociation from calnexin and post-translational trimming of mannose from asparagine-linked oligosaccharides.


INTRODUCTION

Conformational maturation of nascent polypeptides is facilitated by transient physical interaction with molecular chaperones. The general consensus is that rounds of binding prevent misfolding and subsequent entrance of partially folded intermediates into nonproductive folding pathways (1). In eukaryotic cells, nascent polypeptides destined to traverse compartments of the secretory pathway are translocated into the lumen of the endoplasmic reticulum (ER)1 during biosynthesis (2). Incompletely folded proteins often exhibit a persistent physical association with one or more molecular chaperones and are retained in the ER prior to intracellular disposal (for a review, see Ref. 3). This mechanism has been termed "quality control" (4) and apparently functions to ensure transport of only correctly folded proteins beyond the ER.

Calnexin (also designated p88 or IP90), a calcium-binding molecular chaperone of the ER membrane (5), forms a transient noncovalent association with several newly synthesized proteins in the ER (6-14). An important feature of calnexin is that it exhibits an affinity for monoglucosylated oligosaccharides (15), which are intermediates formed during cotranslational trimming by ER alpha -glucosidases (16). Importantly, it can also be generated by post-translational reglucosylation of glycans, an event catalyzed by the ER resident protein UDP-glucose:glycoprotein glucosyltransferase (17-19). Interaction with calnexin can be prevented by drugs that either inhibit asparagine-linked glycosylation or arrest cotranslational trimming of attached glucose residues (6, 7, 20-22) and is virtually nonexistent in mutant cell lines deficient in ER alpha -glucosidase I or II (23).

Protein folding and quality control machinery may participate in the molecular pathogenesis of plasma alpha 1-antitrypsin (AAT) deficiency (24, 25). Human AAT is a monomeric glycoprotein of 394 amino acids (26, 27) and is secreted from liver hepatocytes (28). It is a member of the serine proteinase inhibitor superfamily (29) and protects lung elastin fibers from proteolytic destruction by inhibiting the activity of elastase released from activated neutrophils (30). Several allelic variants of the inhibitor exist (31), and many exhibit a distinct mutation predicted to preclude conformational maturation of the encoded polypeptide following biosynthesis (32). Defective intracellular transport of the aberrantly folded protein through compartments of the secretory pathway can diminish circulating levels of the inhibitor (25). Proteolytic destruction of lung elastin is associated with severe plasma AAT deficiency and is implicated in the pathogenesis of chronic obstructive lung disease (33).

Intracellular retention of most "null" AAT variants results from mutations that cause premature truncation of the polypeptide at its carboxyl terminus (34), a phenomenon predicted to prevent formation of specific secondary structural features (32, 35). In this study, conformation-based quality control of human AAT secretion was investigated in mouse hepatoma cells stably expressing the nonfunctional allelic variant QO Hong Kong (null(Hong Kong)), which is incapable of folding into the appropriate native structure. Null(Hong Kong) exhibits a Ca2+-sensitive physical interaction with the molecular chaperone calnexin during intracellular retention (36) and requires release from the molecular chaperone as well as post-translational trimming of its asparagine-linked oligosaccharides for normal disposal. Predicted roles for each of these events in the quality control of human AAT secretion are discussed.


MATERIALS AND METHODS

Chemicals and Reagents

Protein G-agarose, castanospermine, and 1-deoxymannojirimycin were purchased from Calbiochem. Importantly, 1-deoxymannojirimycin purchased from this source did not inhibit protein synthesis. Tunicamycin (homolog A1), cycloheximide, and all salts and buffers were purchased from Sigma. Easy Tag [35S]methionine was purchased from DuPont NEN. All media used in tissue culture were purchased from Life Technologies, Inc. Fetal bovine serum was procured from Summit Biotechnology.

Antisera

An immunoglobulin fraction of goat anti-human AAT was purchased from Organon Teknika-Cappel. Rabbit polyclonal antisera against a synthetic polypeptide homologous to amino acids 487-505 in the cytoplasmic tail of canine calnexin was a gift from Drs. John J. M. Bergeron (McGill University) and Ari Helenius (Yale University).

Cultured Cells

The cell line H1A/N13 was previously generated by stable transfection of the mouse hepatoma cell line Hepa 1a with subcloned DNA encoding the human null(Hong Kong) AAT variant (37). Cells were maintained as monolayers in Dulbecco's modified Eagle's/Waymouth medium (3:1) containing 15% fetal bovine serum, 1 × glutathione, and 1 × penicillin/streptomycin. The cell line remained under selective pressure with the antibiotic G418 (37).

Metabolic Radiolabeling of Proteins

H1A/N13 cells were maintained in 100-mm diameter dishes. For metabolic radiolabeling of proteins, confluent cell monolayers were washed with phosphate-buffered saline and then incubated for the specified period in methionine-free Dulbecco's modified Eagle's medium containing [35S]methionine (150-300 µCi). A 30-min incubation in methionine-free Dulbecco's modified Eagle's medium preceded addition of radiolabel in all experiments in which the pulse was for 15 min. When appropriate, cells were "chased" by washing monolayers with warmed phosphate-buffered saline and then incubated in regular growth medium containing a 4-fold excess of unlabeled methionine. Inhibitors of oligosaccharide processing activities were added to cells 60 min prior to methionine starvation and were present in pulse-radiolabeling and chase media. Cell lysis was performed by first washing monolayers with cold phosphate-buffered saline, followed by scraping with a rubber spatula in 0.1 M Tris-HCl, pH 7.4, containing 0.5% Nonidet P-40 and a mixture of protease inhibitors (36). Insoluble material was removed by centrifugation for 10 min at 10,000 × g. When appropriate, lysates were frozen on dry ice. A previously described technique (38) was used for immunological detection of radiolabeled human AAT in the insoluble fraction of the cell lysate, but in no case was any detected.

Sucrose Gradient Sedimentation

After metabolic radiolabeling, cells were lysed as described above, and intracellular complexes containing variant null(Hong Kong) were separated by sedimentation in linear 5-20% sucrose gradients as described previously (39). Normally, the lysate generated from a single 100-mm diameter dish of cells was applied to a single gradient. Following centrifugation, gradients were fractionated, from the top, with a Buchler Densi-Flow II apparatus (39) prior to immunoprecipitation of specific proteins.

Immunoprecipitation

Coprecipitation of proteins was performed by incubating soluble cell lysates for 2 h at 4 °C in the presence of protein G-agarose containing specific immobilized antiserum against human AAT or canine calnexin (36). Immunocomplexes were washed by agitation at 4 °C with cell lysis buffer containing 0.5 M NaCl. For detection of newly synthesized null(Hong Kong) bound to calnexin, double immunoprecipitations were performed as described previously (6). For this, calnexin was quantitatively immunoprecipitated from a selected sucrose gradient fraction during a 1-h incubation with a vast excess of anti-calnexin preimmobilized to protein G-agarose. Immunoprecipitates were washed at 4 °C with cell lysis buffer containing 0.5 M NaCl. Coprecipitated null(Hong Kong) was dissociated from the calnexin immunoprecipitate by incubation for 10 min at 37 °C in 0.05 M Tris-HCl, pH 7.4, containing 0.5% Nonidet P-40 and 2 mM EGTA (36), and the immunocomplex was washed twice with 0.5 ml of cell lysis buffer. The supernatant and washes were combined and incubated at 4 °C for 16 h with an excess of anti-human AAT preimmobilized to protein G-agarose for quantitative immunoabsorption of released null(Hong Kong). For fractionation by SDS-PAGE, immunocomplexes were heated for 10 min at 75 °C in disruption buffer containing 2% sodium dodecyl sulfate. Radiolabeled proteins were detected by fluorographic enhancement of the vacuum-dried gel and quantitated by scintillation spectrophotometry of excised gel pieces.

Immunoblotting

Proteins were electrophoretically transferred to Hybond nitrocellulose (Amersham Corp.) following fractionation by SDS-PAGE. Blots were incubated with a 1:1000 dilution of rabbit polyclonal antisera raised against a synthetic polypeptide homologous to amino acids 487-505 in the cytoplasmic tail of canine calnexin (see above). Immunoreactivity was detected by enhanced chemiluminescent Western blotting (ECL, Amersham Corp.) according to the manufacturer's instructions, except that SuperSignal reagent (Pierce) was used as the detection reagent.


RESULTS

Differential Sedimentation of Intracellular Null(Hong Kong) Populations

Variant null(Hong Kong) is not secreted from stably transfected mouse hepatoma cells (37), and its interaction with the molecular chaperone calnexin has been reported (36). Intracellular populations of null(Hong Kong) were separated by sucrose gradient sedimentation and detected by immunoprecipitation following incubation of H1A/N13 cells with [35S]methionine for 5 h (Fig. 1). Approximately 70% of the radiolabeled molecules exhibited a sedimentation coefficient of ~6.8 S (Fig. 1A) and were physically associated with a coprecipitating 90-kDa protein (p90) (Fig. 1B, lane 4) recognized by antiserum against calnexin (Fig. 1C, lane 4). The absence of p90, as well as no detectable immunoreactivity with anti-calnexin in mock-immunoprecipitated material (Fig. 1, B and C, lane 3), was consistent with the previous finding (36) that calnexin is physically associated with variant null(Hong Kong). A smaller population of molecules (~30% of the total) was detected by this method and exhibited a sedimentation coefficient of 4.5 S (Fig. 1A). Coprecipitation of calnexin was not detected (Fig. 1, B and C, compare lanes 1 and 2), consistent with a previous report (39) in which the 4.5 S species was identified as the human AAT monomer.


Fig. 1. Detection of monomeric and calnexin-associated variant null(Hong Kong). H1A/N13 cells were incubated for 5 h with medium containing [35S]methionine, and the soluble cell lysate was subjected to sucrose gradient sedimentation prior to immunoprecipitation of human AAT from gradient fractions. A, the sedimentation profile of immunoprecipitated proteins is expressed as percent of total immunoprecipitating radioactivity associated with variant null(Hong Kong) (NHK) (closed circles) and coprecipitating p90 (open circles). Calculated Svedberg units (S) are shown for each peak. B, shown is a fluorogram after SDS-PAGE of proteins detected in the 4.5 S peak (fraction 12) and 6.8 S peak (fraction 22) following incubation with (lanes and 4) or without (lanes 1 and 3) human AAT antiserum. C, proteins in a gel identical to that in B were electrophoretically transferred to nitrocellulose and incubated with a 1:1000 dilution of antiserum against canine calnexin to detect immunoreactivity by ECL Western blotting. The lanes are identical to those shown in B. Lane 5 is a blank, and lane 6 is a crude cell extract used for detection of endogenous calnexin (Cxn) in H1A/N13 cells.
[View Larger Version of this Image (41K GIF file)]


Cotranslational Assembly with Calnexin

Sucrose gradient sedimentation and coprecipitation techniques were used to characterize the time course of assembly between calnexin and newly synthesized null(Hong Kong). The entire population of newly synthesized molecules radiolabeled during a 15-min incubation with [35S]methionine sedimented at 6.8 S (Fig. 2A). In a double immunoprecipitation analysis, radiolabeled null(Hong Kong) was detected in a calnexin immunoprecipitate generated from the 6.8 S species (Fig. 3A, lane 2). Because less than quantitative coprecipitation may occur by this methodology, an experiment was performed in which the null(Hong Kong)-calnexin interaction was disrupted by chelation of calcium ions (36) prior to sucrose gradient sedimentation. This shifted sedimentation of the entire population of radiolabeled molecules to 4.5 S (Fig. 2A) and coincided with the disappearance of radiolabeled null(Hong Kong) in the calnexin immunoprecipitate (Fig. 3A, lane 4). Importantly, sedimentation of the 6.8 S complex was unaffected in response to an identical incubation without EGTA (data not shown), suggesting that dissociation was specific.


Fig. 2. Cotranslational association with calnexin and evidence for release of monomers. H1A/N13 cells were pulse-radiolabeled for 15 min with medium containing [35S]methionine, and soluble cell lysates were subjected to sucrose gradient sedimentation following the pulse (A) or after a 2-h chase (B) prior to immunoprecipitation of human AAT from selected gradient fractions (closed circles). Also shown are cell lysates incubated for 10 min at 37 °C in the presence of 2 mM EGTA prior to sucrose gradient sedimentation (open circles). Data are expressed as percent of total immunoprecipitating radioactivity. Calculated Svedberg units (S) are shown for individual peaks.
[View Larger Version of this Image (25K GIF file)]



Fig. 3. Detection of pulse-radiolabeled variant null(Hong Kong) bound to calnexin. Double immunoprecipitation analysis (see "Materials and Methods") was carried out on radiolabeled null(Hong Kong) as shown in Fig. 2. A, pulse; B, 2-h chase. Lanes 1, 3, and 5, direct immunoprecipitation of null(Hong Kong) (NHK) with human AAT antiserum (A); lanes 2, 4, and 6, immunoprecipitated null(Hong Kong) following release from a calnexin immunoprecipitate (Cxn right-arrow A). In each case, fraction 12 was used for the 4.5 S peak, and fraction 22 was used for the 6.8 S peak.
[View Larger Version of this Image (35K GIF file)]


Cotranslational Trimming of Glucose from Asparagine-linked Oligosaccharides Is Required for Assembly with Calnexin

Ware et al. (15) have reported that calnexin exhibits an affinity for monoglucosylated oligosaccharides, and for many glycoproteins, interaction with calnexin is prevented by compounds that inhibit asparagine-linked glycosylation or that arrest cotranslational trimming of attached glucose residues (6, 7, 20-22). Since covalent addition of the oligosaccharide moiety Glc3-Man9-GlcNAc2 occurs cotranslationally (16), the necessity of oligosaccharides in generating the null(Hong Kong)-calnexin association was tested by preincubating H1A/N13 cells with tunicamycin prior to pulse radiolabeling (Fig. 4). Inhibition of asparagine-linked glycosylation was confirmed by increased electrophoretic mobility of pulse-radiolabeled molecules (Fig. 4A, panel TUN, lane 1). Assembly with calnexin was not detected (Table I). Since the three terminal glucose residues are subjected to cotranslational hydrolysis (16), cells were preincubated with castanospermine, an inhibitor of ER alpha -glucosidases I and II (16), to maintain the oligosaccharide in the original Glc3-Man9-GlcNAc2 structure. Inhibition of glucose was confirmed by retarded electrophoretic mobility of pulse-radiolabeled null(Hong Kong) (Fig. 4A, panel CST, lane 1). Again, assembly with calnexin was prevented (Table I).


Fig. 4. Asparagine-linked glycosylation and trimming of oligosaccharides effect disposal of nascent null(Hong Kong). A, H1A/N13 cells were preincubated for 1 h with medium containing no additions (CO), tunicamycin (TUN), castanospermine (CST), or 1deoxymannojirimycin (DM) prior to a 15-min pulse with [35S]methionine. Concentrations of each compound are shown in Table I. SDS-PAGE was carried out on cells lysed after the pulse (lane 1) or following 180 min of chase (lane 2) prior to immunoprecipitation and detection of radiolabeled variant null(Hong Kong) (NHK). The mobility of two protein molecular mass markers is shown in kilodaltons, and the asterisk shows the increased mobility of null(Hong Kong) that accompanies its intracellular retention. B, percent of pulse-radiolabeled null(Hong Kong) molecules immunoprecipitated from cells after the 180-min chase is shown in the form of a bar graph. The percent of calnexin-associated molecules (6.8 S peak) is shown in black, and the percent of monomers (4.5 S peak) is shown in white.
[View Larger Version of this Image (31K GIF file)]


Table I.

Asparagine-linked glycosylation and trimming of oligosaccharides effect assembly of nascent null(Hong Kong) with calnexin

H1A/N13 cells were preincubated for 1 h with medium containing no additions (control), tunicamycin, castanospermine, or 1-deoxymannojirimycin prior to a 15-min pulse with [35S]methionine. Cell lysates were subjected to sucrose gradient sedimentation and double immunoprecipitation to detect associated calnexin. The predicted oligosaccharide structure resulting from each treatment is shown.
Preincubationa Inhibits Predicted oligosaccharide structure NHKb associated with calnexinc

%
Control None Man8-9-GlcNAc2 100
Tunicamycin (10 µg/ml) N-Linked glycosylation None present 0
Castanospermine (0.1 mg/ml)  alpha -Glucosidases I and II Glc3-Man9-GlcNAc2 0
Deoxymannojirimycin (1 mM)  alpha -Mannosidase Man9-GlcNAc2 100

a Monolayers were incubated with various inhibitors for 60 min prior to pulse radiolabeling.
b NHK, null(Hong Kong).
c Values were determined by sucrose gradient sedimentation and double immunoprecipitation.

Post-translational Appearance of the 4.5 S Species

Variant null(Hong Kong) undergoes intracellular disposal with a half-life of ~2 h (40). However, enhanced instability was observed in cells preincubated with either tunicamycin or castanospermine as compared with control cells (Fig. 4A), suggesting that interaction with calnexin protects from intracellular proteolysis. Since the entire population of pulse-radiolabeled molecules of variant null(Hong Kong) was bound to calnexin, we asked whether appearance of the 4.5 S monomer population, representing release from calnexin, coincided with the onset of intracellular disposal. Approximately 70% of the radiolabeled molecules continued to sediment at 6.8 S after 2 h of chase (Fig. 2B). Double immunoprecipitation analysis demonstrated their physical interaction with calnexin (Fig. 3B, lane 4). Furthermore, the 6.8 S species was quantitatively shifted to 4.5 S following incubation of the cell lysate with 2 mM EGTA (Fig. 2B), which coincided with loss of interaction with calnexin (Fig. 3B, lane 6). Importantly, ~30% of the radiolabeled molecules sedimented at 4.5 S after the 2-h chase (Fig. 2B), and no physical interaction with calnexin was detected by double immunoprecipitation (Fig. 3B, lane 2). Since the entire population of pulse-radiolabeled molecules was associated with calnexin immediately following biosynthesis (Fig. 2A), detection of the 4.5 S species was consistent with the idea that this population had been released during the chase.

Intracellular Disposal Coincides with Appearance of the 4.5 S Species

Since intracellular disposal of pulse-radiolabeled null(Hong Kong) is preceded by a 45-min lag (40), we asked whether appearance of released monomers coincided with the onset of disposal. The radiolabeled 4.5 S species was not detected until 60 min of chase (Fig. 5). At this time point, 20% of the radiolabeled molecules sedimented at 4.5 S (Fig. 5). Approximately 80% sedimented at 6.8 S, and only these exhibited a physical association with calnexin as judged by double immunoprecipitation analysis and altered sedimentation in response to EGTA (data not shown). Significantly, appearance of the 4.5 S species coincided with the first detectable loss of null(Hong Kong). The ratio of calnexin-associated (6.8 S) and monomeric (4.5 S) molecules remained relatively constant during the next 2 h, during which the majority of molecules were removed from the cell. It should be noted that radiolabeled null(Hong Kong) was not detected in the insoluble portion of the cell lysate (data not shown), which would be expected if loss of immunopreciptable molecules had resulted from their insolubility.


Fig. 5. Intracellular disposal of variant null(Hong Kong) and association with calnexin. H1A/N13 cells were incubated for 15 min with [35S]methionine, and cells were chased for the designated periods prior to sucrose gradient sedimentation of cell lysates and detection of associated calnexin by double immunoprecipitation analysis (see "Materials and Methods"). Data are shown in the form of a bar graph. The percent of calnexin-associated molecules (6.8 S peak) is shown in black, and the percent of monomers (4.5 S peak) is shown in white.
[View Larger Version of this Image (25K GIF file)]


Inhibition of Protein Synthesis Prevents Appearance of the 4.5 S Species and Arrests Intracellular Disposal

Cycloheximide is an inhibitor of protein synthesis and somehow blocks intracellular disposal of several transport-impaired proteins in the secretory pathway (40, 41). Disposal of pulse-radiolabeled null(Hong Kong) was nonexistent during a 3-h chase in medium containing 20 µg/ml cycloheximide (Fig. 6A). Furthermore, the gradual increase in the electrophoretic mobility of variant null(Hong Kong) that normally accompanies its intracellular retention (40) was absent (Fig. 6A, asterisk). Puromycin, another inhibitor of protein biosynthesis, had these same effects (data not shown). Significantly, arrested disposal coincided with our inability to detect the radiolabeled 4.5 S species by sucrose gradient sedimentation (Fig. 6B). Cycloheximide did not reverse the intracellular stability of null(Hong Kong) in cells preincubated with either tunicamycin or castanospermine (Fig. 6B), consistent with the idea that the mechanism of inhibiting disposal required association with calnexin.


Fig. 6. Intracellular disposal of variant null(Hong Kong) and association with calnexin in cells chased with cycloheximide. A, SDS-PAGE was carried out for variant null(Hong Kong) (NHK) in H1A/N13 cells lysed after a 15-min pulse with [35S]methionine (lane 1) or following 180 min of chase in medium containing no additions (lane 2) or 20 µg/ml cycloheximide (CX) (lane 3). The asterisk shows the increased mobility of null(Hong Kong) that accompanies its intracellular retention. B, percent of pulse-radiolabeled null(Hong Kong) molecules immunoprecipitated from cells after the 180-min chase is shown in the form of a bar graph. The percent of calnexin-associated molecules (6.8 S peak) is shown in black, and the percent of monomers (4.5 S peak) is shown in white. Double immunoprecipitation and changes in sedimentation after incubation with EGTA were used to verify the identity of each species. CO, no additions; TUN, tunicamycin; CST, castanospermine; DM, 1-deoxymannojirimycin.
[View Larger Version of this Image (20K GIF file)]


1-Deoxymannojirimycin Arrests Disposal without Affecting Appearance of the 4.5 S Species

Deglycosylation with endoglycosidase H and subsequent fractionation by SDS-PAGE indicated that the gradual increase in the electrophoretic mobility of variant null(Hong Kong) during intracellular retention had resulted from post-translational modification of asparagine-linked oligosaccharides (data not shown). This conclusion was supported by the ability of 1-deoxymannojirimycin, a mannose analog capable of inhibiting the activity of several ER and Golgi alpha -mannosidases (42-45), to prevent this post-translational anomaly (Fig. 4A, panel DM). Preincubation with this mannose analog did not prevent nascent null(Hong Kong) from interacting with calnexin (Table I). However, intracellular disposal of pulse-radiolabeled molecules was completely arrested by this treatment (panel DM). Unlike inhibition during cycloheximide treatment, both the 4.5 S and 6.5 S species were detected in cells after 3 h of chase (Fig. 6B), and their ratio was almost identical to that detected in untreated cells (Fig. 4B). This was no different at the 60-, 120-, and 180-min time points (not shown). Assembly of newly synthesized null(Hong Kong) with calnexin was not affected by preincubation with 1-deoxymannojirimycin (Table I). Furthermore, 1-deoxymannojirimycin did not prevent disposal of null(Hong Kong) in cells coincubated with either tunicamycin or castanospermine (Fig. 4B). This indicated that inhibition of disposal by 1-deoxymannojirimycin required that null(Hong Kong) interact with calnexin. The data suggested that inhibition of alpha -mannosidase activity was responsible for arresting intracellular disposal of variant null(Hong Kong).


DISCUSSION

Since hepatocytes are the major site for biosynthesis and secretion of AAT (28, 46), stably transfected mouse hepatoma cells were used to study conformation-based quality control of human AAT secretion. Variant null(Hong Kong) was employed for this analysis because truncation of amino acids at its carboxyl terminus prevents formation of all three large beta -sheet structures common to members of the serine proteinase inhibitor superfamily (32, 35). The correctly folded variant PI M1(Val-213) is rapidly secreted from these cells, whereas null(Hong Kong) is subjected to intracellular retention and disposal (37, 40). In this study, cosedimentation and coimmunoprecipitation analyses indicated that newly synthesized molecules sedimented at 6.8 S, which coincided with their quantitative association with the molecular chaperone calnexin. This indicates that assembly of the complex occurred cotranslationally or immediately following biosynthesis.

Interaction with calnexin was prevented by inhibiting asparagine-linked glycosylation with tunicamycin or by arresting cotranslational trimming of attached glucose residues with castanospermine. This indicates that like many other glycoproteins (11, 47), oligosaccharides may somehow function to facilitate assembly between null(Hong Kong) and calnexin. Intracellular disposal of nascent null(Hong Kong) was accelerated in cells preincubated with either tunicamycin or castanospermine, suggesting that disposal occurs in the absence of the bound molecular chaperone. This idea was consistent with appearance of the 4.5 S species at a time point that coincided with the onset of intracellular disposal. The absence of associated calnexin and sedimentation at 4.5 S suggests that this population of molecules represents the released monomer (36, 39). No changes in the monomer population were observed when cell lysis was performed under less stringent conditions (data not shown), suggesting that the 4.5 S population does not merely reflect weakening of the null(Hong Kong)-calnexin interaction during retention, but represents unassociated molecules. It should be pointed out that in an earlier report (36), an error in our fractionation method, overlap between the 4.5 S and 6.8 S species, and incomplete dissociation of complexes in response to incubation with EGTA led to the incorrect conclusion that an additional sedimenting species was detected under steady-state conditions. It is now apparent that the most abundant forms of null(Hong Kong) are the 4.5 S and 6.8 S species. However, we cannot rule out the possibility that additional, more transient species exist.

Intracellular disposal of null(Hong Kong) was arrested during incubation of pulse-radiolabeled cells with cycloheximide, and this coincided with complete absence of the 4.5 S monomer population. Cycloheximide had no demonstrable effect on the intracellular stability of null(Hong Kong) in cells preincubated with either tunicamycin or castanospermine, which supported the idea that dissociation from calnexin required protein synthesis. Although our experiments have not addressed the mechanism by which dissociation was inhibited, one possibility is that a short-lived protein is required for normal disruption of the null(Hong Kong)-calnexin complex. Cycloheximide treatment had the added effect of preventing post-translational trimming of oligosaccharides attached to null(Hong Kong). At present, we do not know whether this reflects inaccessibility of glycans for trimming while null(Hong Kong) is bound to calnexin. However, previous experiments have suggested that the null(Hong Kong)-calnexin interaction is stabilized by a peptide-peptide interaction (36). Furthermore, incubation with several combinations of monosaccharides has failed to dissociate the complex after coprecipitation,2 suggesting that the glycan moiety is not involved in stabilizing the interaction after assembly. These data are in agreement with a two-step binding model proposed by Tector and Salter (12) in which the function of the monoglucosylated oligosaccharide is to initiate assembly of glycoproteins with calnexin. However, we cannot disregard the possibility that a lectin-like interaction does exist, but is disrupted during immunoprecipitation.

Intracellular disposal of null(Hong Kong) was also arrested in cells treated with 1-deoxymannojirimycin, which also prevented demonstrable post-translational trimming of asparagine-linked oligosaccharides. Originally, only one alpha -mannosidase activity had been assigned to the ER (16). However, in recent years, several alpha -mannosidases have been identified in the ER, many of which are inhibited by 1-deoxymannojirimycin (42-45). Unlike cycloheximide treatment, in which inhibition of disposal coincided with a complete absence of the 4.5 S peak, inhibition with 1-deoxymannojirimycin did not alter the monomer population. Taken together, data from this study suggest that variant null(Hong Kong) is subjected to a quality control pathway identical to that recently proposed by Hammond and Helenius (11). Their model proposes that persistent association between unfolded glycoproteins and calnexin reflects a continuous cycle of binding in which assembly of the complex is facilitated by reglucosylation of asparagine-linked oligosaccharides by the ER resident enzyme UDP-glucose:glycoprotein glucosyltransferase (17-19, 48). Importantly, the model predicts that permanent dissociation from the binding cycle will occur when hydrolysis of mannose residues generates an oligosaccharide unable to participate as a glucose acceptor, thereby leading to disposal of the unfolded glycoprotein. Consistent with this model, inhibition of oligosaccharide trimming by 1-deoxymannojirimycin abrogated intracellular disposal of variant null(Hong Kong) without affecting the percent population of 4.5 S monomers present in the cell. This latter finding would be expected if the protein is degraded only when it can no longer participate in the cycle of binding to calnexin, which would result after extensive post-translational trimming of glycans by alpha -mannosidase. Further dissection of this quality control pathway will be the subject of future investigations and will enhance our current understanding of how incompletely folded human AAT variants are retained and degraded in hepatocytes.


FOOTNOTES

*   This work was supported in part by an American Heart Association grant-in-aid and an American Lung Association research career investigator award (to R. N. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Dept. of Pathology, Section of Molecular Pathobiology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-3169; Fax: 713-798-5838; E-mail: rsifers{at}bcm.tmc.edu.
1   The abbreviations used are: ER, endoplasmic reticulum; AAT, alpha 1-antitrypsin; PAGE, polyacrylamide gel electrophoresis.
2   R. N. Sifers, unpublished data.

Acknowledgments

We thank Drs. John J. M. Bergeron and Ari Helenius for gifts of specific antisera to calnexin.


REFERENCES

  1. Gething, M. J., and Sambrook, J. (1992) Nature 355, 33-45 [CrossRef][Medline] [Order article via Infotrieve]
  2. Walter, P., Gilmore, R., and Blobel, G. (1984) Cell 38, 5-8 [Medline] [Order article via Infotrieve]
  3. Klausner, R. D., and Sitia, R. (1990) Cell 62, 611-614 [Medline] [Order article via Infotrieve]
  4. Hurtley, S. M., and Helenius, A. (1989) Annu. Rev. Cell Biol. 5, 277-307 [CrossRef]
  5. Wada, I., Rindress, D., Cameron, P. H., Ou, W.-J., Doherty, J. J., II, Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610 [Abstract/Free Full Text]
  6. Ou, W.-J., Cameron, P. H., Thomas, D. Y., and Bergeron, J. M. (1993) Nature 364, 771-776 [CrossRef][Medline] [Order article via Infotrieve]
  7. Hammond, C., Braakman, I., and Helenius, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 913-917 [Abstract]
  8. Wada, I., Ou, W.-J., Liu, M.-C., and Scheele, G. (1994) J. Biol. Chem. 269, 7464-7472 [Abstract/Free Full Text]
  9. Pind, S., Riordan, J. R., and Williams, D. B. (1994) J. Biol. Chem. 269, 12784-12788 [Abstract/Free Full Text]
  10. Jackson, M. R., Cohen-Doyle, M. F., Peterson, P. A., and Williams, D. B. (1994) Science 263, 384-387 [Medline] [Order article via Infotrieve]
  11. Hammond, C., and Helenius, A. (1994) Science 266, 456-458 [Medline] [Order article via Infotrieve]
  12. Tector, M., and Salter, R. D. (1995) J. Biol. Chem. 270, 19638-19642 [Abstract/Free Full Text]
  13. Kim, P. S., and Arvan, P. (1995) J. Cell Biol. 128, 29-38 [Abstract]
  14. van Leeuwen, J. E. M., and Kearse, K. P. (1996) J. Biol. Chem. 271, 9660-9665 [Abstract/Free Full Text]
  15. Ware, F. E., Vassilakos, A., Peterson, P. A., Jackson, M. R., Lehrman, M. A., and Williams, D. B. (1995) J. Biol. Chem. 270, 4697-4704 [Abstract/Free Full Text]
  16. Kornfeld, R., and Kornfeld, S. (1985) Annu. Rev. Biochem. 54, 631-664 [CrossRef][Medline] [Order article via Infotrieve]
  17. Trombetta, S., Bosch, M., and Parodi, A. J. (1989) Biochemistry 28, 8108-8116 [Medline] [Order article via Infotrieve]
  18. Sousa, M. C., Ferrero-Garcia, M. A., and Parodi, A. J. (1992) Biochemistry 31, 97-105 [Medline] [Order article via Infotrieve]
  19. Trombetta, S. E, Ganan, S., and Parodi, A. J. (1991) Glycobiology 1, 155-161 [Abstract]
  20. Moore, S. E. H., and Spiro, R. G. (1993) J. Biol. Chem. 268, 3809-3812 [Abstract/Free Full Text]
  21. Kearse, K. P., Williams, D. B., and Singer, A. (1994) EMBO J. 13, 3678-3686 [Abstract]
  22. Hebert, D. N., Foellmer, B., and Helenius, A. (1995) Cell 81, 425-433 [Medline] [Order article via Infotrieve]
  23. Ora, A., and Helenius, A. (1995) J. Biol. Chem. 270, 26060-26062 [Abstract/Free Full Text]
  24. Sifers, R. N., Finegold, M. J., and Woo, S. L. C. (1989) Am. J. Respir. Cell Mol. Biol. 1, 341-345 [Medline] [Order article via Infotrieve]
  25. Sifers, R. N., Finegold, M. J., and Woo, S. L. C. (1994) in The Liver: Biology and Pathobiology (Arias, I. M., Boyer, J. L., Fausto, N., Jakoby, W. B., Schachter, D. A., and Shafritz, D. A., eds), 3rd Ed., pp. 1357-1365, Raven Press, Ltd., New York
  26. Carrell, R. W., and Boswell, D. R. (1986) in Proteinase Inhibitors (Barrett, A. J., and Salvesen, G., eds), pp. 403-420, Elsevier Science Publishers B. V., Amsterdam
  27. Long, G. L., Chandra, T., Woo, S. L. C., Davie, W. W., and Kurache, K. (1984) Biochemistry 23, 4828-4837 [Medline] [Order article via Infotrieve]
  28. Peters, T., Jr. (1983) in Plasma Protein Secretion by the Liver (Glaumann, H., Peters, T., Jr., and Redman, C., eds), pp. 1-5, Academic Press, New York
  29. Huber, R., and Carrell, R. W. (1989) Biochemistry 28, 8951-8966 [Medline] [Order article via Infotrieve]
  30. Travis, J., and Salvesen, G. S. (1983) Annu. Rev. Biochem. 52, 655-709 [CrossRef][Medline] [Order article via Infotrieve]
  31. Brantly, M., Nukiwa, Y., and Crystal, R. G. (1988) Am. J. Med. 84, 13-31 [Medline] [Order article via Infotrieve]
  32. Stein, P. E., and Carrell, R. W. (1995) Nat. Struct. Biol. 2, 96-113 [Medline] [Order article via Infotrieve]
  33. Beith, J. (1978) Front. Matrix Biol. 6, 1-4
  34. Fabretti, G., Sergi, C., Consales, G., Faa, G., Brisigotti, M., Romeo, G., and Callea, F. (1992) Liver 12, 296-301 [Medline] [Order article via Infotrieve]
  35. Loebermann, H., Tobuoka, R., Deisenhofer, J., and Huber, R. (1984) J. Mol. Biol. 177, 531-556 [Medline] [Order article via Infotrieve]
  36. Le, A., Steiner, J. L., Ferrell, G. A, Shaker, J. C., and Sifers, R. N. (1994) J. Biol. Chem. 269, 7514-7519 [Abstract/Free Full Text]
  37. Sifers, R. N., Brashears-Macatee, S., Kidd, V. J., Muensch, H., and Woo, S. L. C. (1988) J. Biol. Chem. 263, 7330-7335 [Abstract/Free Full Text]
  38. Graham, K. S., Le, A., and Sifers, R. N. (1990) J. Biol. Chem. 265, 20463-20468 [Abstract/Free Full Text]
  39. Le, A., Ferrell, G. A., Dishon, D. S., Le, Q.-Q. A., and Sifers, R. N. (1992) J. Biol. Chem. 267, 1072-1080 [Abstract/Free Full Text]
  40. Le, A., Graham, K. S., and Sifers, R. N. (1990) J. Biol. Chem. 265, 14001-14007 [Abstract/Free Full Text]
  41. Wikstrom, L., and Lodish, H. F. (1990) J. Cell Biol. 113, 997-1002 [Abstract]
  42. Rizzolo, L. J., and Kornfeld, R. (1988) J. Biol. Chem. 263, 9520-9525 [Abstract/Free Full Text]
  43. Elbein, A. D. (1991) FASEB J. 5, 3055-3063 [Abstract/Free Full Text]
  44. Bause, E., Breuer, W., Schweden, J., Roeser, R., and Geyer, R. (1992) Eur. J. Biochem. 208, 451-457 [Abstract]
  45. Bonay, P., Roth, J., and Hughes, C. (1992) Eur. J. Biochem. 205, 399-407 [Abstract]
  46. Sifers, R. N., Carlson, J. A., Clift, S. M., DeMayo, F. J., Bullock, D. W., and Woo, S. L. C. (1987) Nucleic Acids Res. 15, 1459-1475 [Abstract]
  47. Helenius, A. (1994) Mol. Biol. Cell 5, 253-265 [Medline] [Order article via Infotrieve]
  48. Ganan, S., Cazzulo, J. J., and Parodi, A. J. (1991) Biochemistry 30, 3098-3104 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.